JP2019518427A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518427A5 JP2019518427A5 JP2018554334A JP2018554334A JP2019518427A5 JP 2019518427 A5 JP2019518427 A5 JP 2019518427A5 JP 2018554334 A JP2018554334 A JP 2018554334A JP 2018554334 A JP2018554334 A JP 2018554334A JP 2019518427 A5 JP2019518427 A5 JP 2019518427A5
- Authority
- JP
- Japan
- Prior art keywords
- itr
- seq
- raav
- rbg
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006194 liquid suspension Substances 0.000 claims 8
- 241000702421 Dependoparvovirus Species 0.000 claims 7
- 238000002347 injection Methods 0.000 claims 5
- 239000007924 injection Substances 0.000 claims 5
- 210000000234 capsid Anatomy 0.000 claims 4
- 108091026890 Coding region Proteins 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 102000007469 Actins Human genes 0.000 claims 2
- 108010085238 Actins Proteins 0.000 claims 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 2
- 241000271566 Aves Species 0.000 claims 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102100037935 Polyubiquitin-C Human genes 0.000 claims 1
- 108010056354 Ubiquitin C Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022046261A JP7111924B2 (ja) | 2016-04-15 | 2022-03-23 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2022116098A JP7492556B2 (ja) | 2016-04-15 | 2022-07-21 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2024080598A JP2024105617A (ja) | 2016-04-15 | 2024-05-17 | 滲出型加齢性黄斑変性の治療のための組成物 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323184P | 2016-04-15 | 2016-04-15 | |
| US62/323,184 | 2016-04-15 | ||
| US201662331100P | 2016-05-03 | 2016-05-03 | |
| US62/331,100 | 2016-05-03 | ||
| US201762442946P | 2017-01-05 | 2017-01-05 | |
| US62/442,946 | 2017-01-05 | ||
| US201762460515P | 2017-02-17 | 2017-02-17 | |
| US62/460,515 | 2017-02-17 | ||
| US201762466721P | 2017-03-03 | 2017-03-03 | |
| US62/466,721 | 2017-03-03 | ||
| PCT/US2017/027529 WO2017180936A1 (en) | 2016-04-15 | 2017-04-14 | Compositions for treatment of wet age-related macular degeneration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022046261A Division JP7111924B2 (ja) | 2016-04-15 | 2022-03-23 | 滲出型加齢性黄斑変性の治療のための組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019518427A JP2019518427A (ja) | 2019-07-04 |
| JP2019518427A5 true JP2019518427A5 (enExample) | 2020-05-28 |
| JP7046828B2 JP7046828B2 (ja) | 2022-04-04 |
Family
ID=59253994
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554334A Active JP7046828B2 (ja) | 2016-04-15 | 2017-04-14 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2022046261A Active JP7111924B2 (ja) | 2016-04-15 | 2022-03-23 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2022116098A Active JP7492556B2 (ja) | 2016-04-15 | 2022-07-21 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2024080598A Pending JP2024105617A (ja) | 2016-04-15 | 2024-05-17 | 滲出型加齢性黄斑変性の治療のための組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022046261A Active JP7111924B2 (ja) | 2016-04-15 | 2022-03-23 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2022116098A Active JP7492556B2 (ja) | 2016-04-15 | 2022-07-21 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2024080598A Pending JP2024105617A (ja) | 2016-04-15 | 2024-05-17 | 滲出型加齢性黄斑変性の治療のための組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11197937B2 (enExample) |
| EP (1) | EP3452103A1 (enExample) |
| JP (4) | JP7046828B2 (enExample) |
| KR (2) | KR102574810B1 (enExample) |
| AU (2) | AU2017248731B2 (enExample) |
| CA (1) | CA3019426A1 (enExample) |
| IL (2) | IL322403A (enExample) |
| MA (1) | MA44873A (enExample) |
| SG (2) | SG11201808426XA (enExample) |
| WO (1) | WO2017180936A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| KR20200060456A (ko) * | 2017-09-27 | 2020-05-29 | 리젠엑스바이오 인크. | 완전-인간 번역후 변형된 항-VEGF Fab를 이용한 안구 질환의 치료 |
| AU2018350990A1 (en) * | 2017-10-18 | 2020-05-21 | Regenxbio Inc. | Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap |
| AU2018372235B9 (en) * | 2017-11-27 | 2022-03-10 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
| JP2021506861A (ja) | 2017-12-19 | 2021-02-22 | アコーオス インコーポレイテッド | 内耳への治療用抗体のａａｖ媒介送達 |
| US20210093734A1 (en) * | 2018-02-20 | 2021-04-01 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-realted macular degeneration |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| JP2022049718A (ja) * | 2019-02-05 | 2022-03-30 | アステラス製薬株式会社 | アデノ随伴ウイルスを用いたｃｘ３ｃｌ１遺伝子の導入による網膜変性疾患の治療 |
| CN113966236A (zh) | 2019-04-03 | 2022-01-21 | 再生生物股份有限公司 | 眼睛病状的基因疗法 |
| BR112021021156A2 (pt) * | 2019-04-24 | 2022-02-08 | Regenxbio Inc | Terapêuticos anticorpos totalmente humanos pós-tradução modificados |
| WO2020243659A1 (en) * | 2019-05-31 | 2020-12-03 | University Of Florida Research Foundation, Incorporated | Vector-based therapy for thyroid disease |
| WO2021041373A1 (en) | 2019-08-26 | 2021-03-04 | Regenxbio Inc. | Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab |
| CN114728049A (zh) | 2019-10-07 | 2022-07-08 | 再生生物股份有限公司 | 腺相关病毒载体药物组合物和方法 |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021231491A1 (en) * | 2020-05-11 | 2021-11-18 | University Of Florida Research Foundation, Incorporated | Disease correction by delivery of aav8 vectors expressing codon optimized naglu |
| TW202208622A (zh) * | 2020-05-12 | 2022-03-01 | 賓州大學委員會 | 用於治療克拉培氏病之組成物 |
| WO2021255589A1 (en) * | 2020-06-16 | 2021-12-23 | Intas Pharmaceuticals Ltd. | An anti-vegf scfab adeno-associated virus (aav) vector and uses thereof |
| WO2021255590A1 (en) * | 2020-06-16 | 2021-12-23 | Intas Pharmaceuticals Ltd. | An anti-vegf scfv adeno-associated virus (aav) vector and uses thereof |
| CN113952473A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| AU2021362770A1 (en) * | 2020-10-16 | 2022-12-08 | Gyroscope Therapeutics Limited | Nucleic acid encoding an anti-VEGF entity and a negative complement regulator and uses thereof for the treatment of age-related macular degeneration |
| CN116528892A (zh) * | 2020-10-28 | 2023-08-01 | 再生生物股份有限公司 | 用于眼部适应症的载体化抗TNF-α抗体 |
| CN116457373A (zh) * | 2020-10-29 | 2023-07-18 | 再生生物股份有限公司 | 用于眼部适应症的载体化TNF-α拮抗剂 |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| EP4284335A1 (en) | 2021-02-01 | 2023-12-06 | RegenxBio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| AU2023215253A1 (en) * | 2022-02-02 | 2024-09-19 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| AU2023250660A1 (en) | 2022-04-06 | 2024-10-24 | Regenxbio Inc. | Pharmaceutical composition comprising a recombinant adenoassociated virus vector with an expression cassette encoding a transgene for suprachoroidal administration |
| IL319873A (en) | 2022-09-30 | 2025-05-01 | Regenxbio Inc | Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB |
| WO2025073297A1 (zh) * | 2023-10-06 | 2025-04-10 | 甘李药业股份有限公司 | 表达抗vegf融合蛋白的aav病毒载体及其用途 |
| WO2025160405A1 (en) * | 2024-01-24 | 2025-07-31 | Duke University | Compositions and methods for generation and secretion of aav particles |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL310327A1 (en) | 1993-02-12 | 1995-12-11 | Univ Leland Stanford Junior | Adjustable transcription of target genes and other biological processes |
| CA2209183A1 (en) | 1994-12-29 | 1996-07-11 | Joel L. Pomerantz | Chimeric dna-binding proteins |
| CA2219080A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamycin-based regulation of biological events |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| JP2003524368A (ja) | 1997-08-26 | 2003-08-19 | アリアド ジーン セラピューティクス インコーポレイテッド | ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白 |
| AU752129B2 (en) | 1997-08-27 | 2002-09-05 | Ariad Gene Therapeutics, Inc. | Chimeric transcriptional activators and compositions and uses related thereto |
| AU755784B2 (en) | 1998-01-15 | 2002-12-19 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using multimeric chimeric proteins |
| CA2319492A1 (en) | 1998-02-13 | 1999-08-19 | President And Fellows Of Harvard College | Novel dimerizing agents, their production and use |
| DE60039766D1 (de) | 1999-08-09 | 2008-09-18 | Targeted Genetics Corp | Terologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen |
| US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
| WO2001029242A2 (en) | 1999-10-21 | 2001-04-26 | Monsanto Company | Post-translational modification of recombinant proteins produced in plants |
| GB2362884A (en) | 2000-05-30 | 2001-12-05 | Isis Innovation | Extended duration of airway gene therapy |
| CN1461342A (zh) | 2000-07-26 | 2003-12-10 | 路德维格癌症研究所 | 糖基化vegf－b和增加可溶性vegf－b量的方法 |
| CA2915124C (en) | 2001-11-13 | 2018-08-14 | The Trustees Of The University Of Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| ES2602352T3 (es) | 2001-12-17 | 2017-02-20 | The Trustees Of The University Of Pennsylvania | Secuencias de serotipo 8 de virus adenoasociado (VAA), vectores que las contienen y usos de las mismas |
| WO2003068801A2 (en) | 2002-02-11 | 2003-08-21 | Genentech, Inc. | Antibody variants with faster antigen association rates |
| US20040208847A1 (en) | 2003-03-28 | 2004-10-21 | Fabienne Rolling | Method and vectors for selectively transducing retinal pigment epithelium cells |
| EP2298926A1 (en) | 2003-09-30 | 2011-03-23 | The Trustees of The University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| EP2357010B1 (en) | 2005-04-07 | 2013-06-12 | The Trustees of The University of Pennsylvania | Method of increasing the function of an AAV vector |
| US7456683B2 (en) | 2005-06-09 | 2008-11-25 | Panasonic Corporation | Amplitude error compensating device and quadrature skew error compensating device |
| CL2008003218A1 (es) | 2007-10-30 | 2009-03-06 | Genentech Inc | Método para la purificación de un anticuerpo a partir de una composición que comprende el anticuerpo y al menos un contaminante. |
| TWI580694B (zh) | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-ｖｅｇｆ抗體 |
| KR101010352B1 (ko) | 2008-05-30 | 2011-01-25 | 삼성중공업 주식회사 | 전력 제어 장치 및 방법 |
| EP2356270B1 (en) | 2008-11-07 | 2016-08-24 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| US8734809B2 (en) * | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| PE20120622A1 (es) | 2009-06-17 | 2012-05-26 | Abbott Biotherapeutics Corp | Anticuerpos anti-vegf y sus usos |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| US8663624B2 (en) * | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| CN107828820B (zh) | 2010-10-27 | 2022-06-07 | 学校法人自治医科大学 | 用于向神经系统细胞导入基因的腺相关病毒粒子 |
| EP4234571A3 (en) | 2011-02-10 | 2023-09-27 | The University of North Carolina at Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| JP6091435B2 (ja) * | 2011-02-22 | 2017-03-08 | カリフォルニア インスティチュート オブ テクノロジー | アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達 |
| RS66184B1 (sr) | 2011-04-22 | 2024-12-31 | Univ California | Adeno-povezani virioni virusa sa varijantama kapsida i postupci za njihovu primenu |
| EP2559443A1 (en) | 2011-08-16 | 2013-02-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject |
| ES2857773T5 (es) | 2011-08-24 | 2024-06-04 | Univ Leland Stanford Junior | Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos |
| US20130090375A1 (en) * | 2011-10-06 | 2013-04-11 | Cornell University | Virus-mediated delivery of bevacizumab for therapeutic applications |
| EP2847337A4 (en) | 2012-05-09 | 2016-04-27 | Univ Oregon Health & Science | ADENO ASSOCIATED VIRUS PLASMIDS AND VECTORS |
| TWI775096B (zh) | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| CA3240136A1 (en) | 2012-11-08 | 2014-05-15 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| US9567376B2 (en) | 2013-02-08 | 2017-02-14 | The Trustees Of The University Of Pennsylvania | Enhanced AAV-mediated gene transfer for retinal therapies |
| EP2970946A4 (en) | 2013-03-13 | 2016-09-07 | Philadelphia Children Hospital | ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF |
| EP3747998B1 (en) | 2013-03-15 | 2024-07-24 | The Trustees of the University of Pennsylvania | Compositions for treating mpsi |
| US9585971B2 (en) | 2013-09-13 | 2017-03-07 | California Institute Of Technology | Recombinant AAV capsid protein |
| JP6552511B2 (ja) | 2013-10-11 | 2019-07-31 | マサチューセッツ アイ アンド イヤー インファーマリー | 祖先ウイルス配列を予測する方法およびその使用 |
| HRP20211015T1 (hr) | 2013-12-03 | 2021-10-01 | Hookipa Biotech Gmbh | Cjepivo protiv citomegalovirusa (cmv) |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| WO2015164757A1 (en) | 2014-04-25 | 2015-10-29 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| WO2015164778A1 (en) | 2014-04-25 | 2015-10-29 | The Trustees Of The University Of Pennysylvania | Ldlr variants and their use in compositions for reducing cholesterol levels |
| SG11201609207SA (en) * | 2014-05-13 | 2016-12-29 | Univ Pennsylvania | Compositions comprising aav expressing dual antibody constructs and uses thereof |
| WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
| US9840553B2 (en) * | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US10064752B2 (en) | 2014-09-11 | 2018-09-04 | Orbit Biomedical Limited | Motorized suprachoroidal injection of therapeutic agent |
| CA2977355A1 (en) | 2015-02-20 | 2016-08-25 | University Of Iowa Research Foundation | Methods and compositions for treating genetic eye diseases |
| CN108135994B (zh) * | 2015-05-13 | 2022-01-25 | 宾夕法尼亚州大学信托人 | Aav-介导的抗-流感抗体的表达及其使用方法 |
| US20190292250A1 (en) | 2015-08-31 | 2019-09-26 | The Trustees Of The University Of Pennsylvania | Aav-anti-vegf for treating cancer in companion animals |
| GB201519086D0 (en) | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
| EP3400014A1 (en) | 2016-01-08 | 2018-11-14 | Clearside Biomedical, Inc. | Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics |
| AU2017250797A1 (en) | 2016-04-15 | 2018-10-25 | Regenxbio Inc. | Treatment of ocular diseases with fully-human post-translationally modified anti-VEGF fab |
| KR20200060456A (ko) | 2017-09-27 | 2020-05-29 | 리젠엑스바이오 인크. | 완전-인간 번역후 변형된 항-VEGF Fab를 이용한 안구 질환의 치료 |
| CN113966236A (zh) | 2019-04-03 | 2022-01-21 | 再生生物股份有限公司 | 眼睛病状的基因疗法 |
-
2017
- 2017-04-14 MA MA044873A patent/MA44873A/fr unknown
- 2017-04-14 WO PCT/US2017/027529 patent/WO2017180936A1/en not_active Ceased
- 2017-04-14 IL IL322403A patent/IL322403A/en unknown
- 2017-04-14 KR KR1020187032620A patent/KR102574810B1/ko active Active
- 2017-04-14 EP EP17734161.7A patent/EP3452103A1/en active Pending
- 2017-04-14 AU AU2017248731A patent/AU2017248731B2/en active Active
- 2017-04-14 JP JP2018554334A patent/JP7046828B2/ja active Active
- 2017-04-14 CA CA3019426A patent/CA3019426A1/en active Pending
- 2017-04-14 KR KR1020237029712A patent/KR20230130765A/ko active Pending
- 2017-04-14 IL IL262207A patent/IL262207B1/en unknown
- 2017-04-14 US US16/093,420 patent/US11197937B2/en active Active
- 2017-04-14 SG SG11201808426XA patent/SG11201808426XA/en unknown
- 2017-04-15 SG SG10201913159UA patent/SG10201913159UA/en unknown
-
2021
- 2021-06-07 US US17/340,752 patent/US20220288238A1/en active Pending
-
2022
- 2022-03-23 JP JP2022046261A patent/JP7111924B2/ja active Active
- 2022-07-21 JP JP2022116098A patent/JP7492556B2/ja active Active
-
2024
- 2024-05-17 JP JP2024080598A patent/JP2024105617A/ja active Pending
- 2024-08-23 AU AU2024216307A patent/AU2024216307A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019518427A5 (enExample) | ||
| JP2024016207A5 (enExample) | ||
| FI3717636T3 (fi) | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä | |
| JPWO2019164854A5 (enExample) | ||
| JP2020114218A5 (enExample) | ||
| JP2020028308A5 (enExample) | ||
| US20210130413A1 (en) | Modified aav capsids and uses thereof | |
| JP2020528734A5 (enExample) | ||
| JP2018508519A5 (enExample) | ||
| RU2016135771A (ru) | Композиции и способы лечения и предотвращения дегенерации желтого пятна | |
| JP2020510424A5 (enExample) | ||
| JP2015523060A5 (enExample) | ||
| JP2017506230A5 (enExample) | ||
| JP2018527941A5 (enExample) | ||
| CA2995849A1 (en) | Chimeric aav-anti-vegf for treating cancer in canines | |
| JP2018510620A5 (enExample) | ||
| US20190240328A1 (en) | Novel humanized anti-ebola antibodies useful in preventing ebola infections | |
| US20200297869A1 (en) | Sequential intravitreal administration of aav gene therapy to contralateral eyes | |
| US20130090375A1 (en) | Virus-mediated delivery of bevacizumab for therapeutic applications | |
| JP2025118913A (ja) | 血管新生に関連する眼疾患の処置のための組成物および方法 | |
| CN119585299A (zh) | 编码抗vegf实体和补体负调节剂的核酸及其用于年龄相关性黄斑变性的治疗的用途 | |
| JPWO2021243085A5 (enExample) | ||
| JPWO2021041373A5 (enExample) | ||
| US20250074974A1 (en) | Angiogenesis inhibitor-conjugated anti-c3b antibody or anti-c5 antibody and use thereof | |
| CN117736274A (zh) | 一种腺相关病毒衣壳蛋白及其用途 |